Change in Coronary Microcirculation and FFR After TAVI in Patients With Cardiovascular Comorbidities
NCT ID: NCT04663334
Last Updated: 2023-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
29 participants
OBSERVATIONAL
2020-12-08
2023-05-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Severe aortic stenosis is the most common indication of valvular replacement in developed countries. Stable coronary artery disease (CAD) is frequently associated with severe aortic stenosis in patients treated by Transcatheter Aortic Valvular Implantation (TAVI). Its prognostic impact is not clearly established, and available studies uncommonly used functional assessment of severity from a coronary stenosis to stratify the risk in this situation.
Fractional Flow Reserve (FFR) is recommended to guide revascularization by percutaneous coronary intervention (PCI) in clinical practice. Its use is not validated in patients with severe aortic stenosis. Left ventricular hypertrophy induced by aortic obstruction leading to microvascular disorders, and can alter coronary reserve, possibly biasing FFR values. After aortic valvular replacement, a myocardial reverse remodeling is described, generating a decrease in hypertrophy, interstitial oedema, and inflammation. Its effect on coronary microcirculatory reserve is not known. Some studies have shown improvement in coronary reserve immediately after TAVI and this effect seemed to last long after treatment.
The aim of the study is to assess the effects of inverse myocardial remodeling on coronary microcirculatory function and its association with FFR values before and after TAVI.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All patients have severe symptomatic aortic stenosis, secondary to degenerative disease confirmed by transthoracic echocardiography (mean gradient \>40 mmHg and/or valve area \<1 cm2) and significant epicardial coronary stenosis (\> or = 50%) assessed by coronarography performed in systematic preoperative work-up. These patients are deemed for TAVI and a first-line medical treatment for CAD, after heart team decision.
The collegially chosen strategy to manage CAD in this population consists in assessing hemodynamic parameters from a coronary stenosis during the TAVI procedure, using functionals tests for ischemia (FFR, IMR, CFR) from a concomitant coronarography. Patients will be routinely admitted in hospital 6 months after TAVI, for clinical and echocardiographic reassessment, and coronarography control. Functional tests will be repeated and according to results, continuation of medical therapy or PCI is proposed, at operator's discretion.
All procedures are performed within the same site by 1 medical team including 4 interventional cardiologists.
Before the TAVI procedure, a computerized multi-sliced tomography is systematically performed to validate the percutaneous approach by femoral access and to choose which prothesis model will be used.
In most cases, TAVI procedure are performed under local anesthesia and mild sedation, under anesthetist supervision.
The common femoral artery is punctured by percutaneous approach, above the femoral bifurcation and a 16-French sheath is inserted.
Three available models of aortic bioprothesis are implanted in our center, the Sapien 3 (EDWARDS Lifescience) the Corevalve Evolute R (Metdtronik) and the Accurate Neo 2 (Boston Scientific) Two Perclose ProGlide devices (Abbott Vascular) are used to perform the perpendicular preclosing. After the deployment of the prosthesis, the TAVI sheath is removed and the nodes from the two previously placed ProGlide devices are tightened. Final femoral angiographic control is not systematic.
Concomitant coronarography is performed by radial artery access site, using a 6-French sheath.
Hemodynamics measures are recorded by PressureWire X Guidewire (Abott Vascular) wireless devices to a computer and processed by the CoroFlow Coroventis software (Abbott Vascular) to carry out multimodal physiological evaluation. FFR, CFR, and IMR measures will be repeated before and immediately after valve implantation. These parameters will be reassessed 6 months after TAVI.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
inverse myocardial remodeling
a myocardial reverse remodeling is described, generating a decrease in hypertrophy, interstitial oedema, and inflammation. Its effect on coronary microcirculatory reserve is not known. Some studies have shown improvement in coronary reserve immediately after TAVI and this effect seemed to last long after treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients with severe symptomatic aortic stenosis secondary to degenerative disease confirmed by transthoracic echocardiography (mean gradient \>40 mmHg and/or valve area \<1 cm2) and with significant coronary artery disease (epicardial coronary stenosis angiography \> or = to 50%)
Exclusion Criteria
* Lack of viability in myocardial territory of interest
* History of bypass coronary surgery or heart transplantation
* Severe left ventricular systolic dysfunction, characterized by an ejection fraction \< 35 %
* Severe renal impairment (Creatinine clearance \<30 ml/min/1.73 m2)
* Absolute contraindication to intravenous adenosin
* Pregnant or nursing women Patients under guardianship, curatorship, or protection of justice
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nantes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thierry Manigold
Role: STUDY_DIRECTOR
Nantes University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Nantes
Nantes, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Battistolo Q, Le Ruz R, Piriou PG, Guerin P, Letocart V, Plessis J, Poinas A, Senage T, Manigold T. Changes in microcirculation following transcatheter aortic valve implantation in patients with stable coronary artery disease. Arch Cardiovasc Dis. 2025 Apr;118(4):222-230. doi: 10.1016/j.acvd.2024.12.006. Epub 2024 Dec 21.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AP001
Identifier Type: -
Identifier Source: org_study_id